Aspirin News and Research

RSS

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.

NHS comes up with a list of 20 most painful conditions

The NHS has listed 20 most painful conditions that are such excruciatingly painful that they can lead to severe debilitation that prevents a person from performing their daily activity.

29 Oct 2018

Aspirin may be effective in preventing blood clots after knee replacement

When it comes to preventing blood clots after a knee replacement, good old aspirin may be just as effective as newer, more expensive drugs.

22 Oct 2018

Inflammatory proteins in the colon increase in parallel with increasing weight, study shows

Studies in mice have demonstrated that obesity-induced inflammation contributes to the risk of colorectal cancer, but evidence in humans has been scarce.

11 Oct 2018

Low-dose aspirin use associated with reduced ovarian cancer risk

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to nonaspirin users.

4 Oct 2018

Aspirin shown to prevent the spread of cancer

New research by Cardiff University has demonstrated a role for Aspirin in the treatment of bowel, prostate and breast cancer.

1 Oct 2018

ASPREE trial explores whether low dose aspirin can prolong good health in elderly people

The ASPREE trial of more than 19,000 participants in Australia and the US is the largest and most comprehensive study to look at whether the many millions of older people around the world who take (100mg) low dose aspirin to preserve good health are deriving any benefit by doing so.

18 Sep 2018

Daily low-dose aspirin does not prolong healthy life in older people, study finds

In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (life free of dementia or persistent physical disability).

17 Sep 2018

The use of aspirin in elderly now questioned

A large study led by Australian researchers has found that taking Aspirin tablets regularly to does not really prolong life or reduce the risk of a first heart attack or stroke.

16 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

New statement provides detailed overview of how to diagnose, treat resistant hypertension

Resistant hypertension affects 12 percent to15 percent of patients treated for high blood pressure according to a new scientific statement from the American Heart Association.

14 Sep 2018

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.

11 Sep 2018

Heart attack and stroke prevention efforts need a boost says CDC

According to a new report from the Centers for Disease Control and Prevention (CDC), the efforts to prevent heart attacks and strokes in the United States have reached a plateau and are not making any further progress.

7 Sep 2018

Major bleeding associated with subsequent cancer diagnoses

Bleeding in patients treated with anticoagulants should stimulate a search for cancer, according to late breaking results from the COMPASS trial presented today at ESC Congress 2018.

28 Aug 2018

Combined oral anticoagulant and antiplatelet therapy linked to poor prognosis in atrial fibrillation

Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients without a clear indication for antiplatelets, according to late breaking results from the GARFIELD-AF registry presented today at ESC Congress 2018.

28 Aug 2018

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear.

28 Aug 2018

Low dose Aspirin daily – benefits and risks measured in two studies

Low dose Aspirin has been advocated to reduce the risk of a second heart attack or a stroke or other heart problems in persons who have had one episode. A major new study published in the Lancet, has found that taking Aspirin to prevent the first heart attack fails to work. In fact the risks of taking low dose Aspirin to prevent the first heart attack outweigh the benefits.

27 Aug 2018

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.

27 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Cardiovascular disease patients with internal bleeding more likely to be diagnosed with cancer

Patients with cardiovascular disease who develop major internal bleeding are much more likely to be diagnosed with cancer, a large international clinical trial has found.

27 Aug 2018

Aspirin appears to cause major bleeds and have no effect on cancers

Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers.

27 Aug 2018

Aspirin News and Research

NHS comes up with a list of 20 most painful conditions

Aspirin may be effective in preventing blood clots after knee replacement

Inflammatory proteins in the colon increase in parallel with increasing weight, study shows

Low-dose aspirin use associated with reduced ovarian cancer risk

Aspirin shown to prevent the spread of cancer

ASPREE trial explores whether low dose aspirin can prolong good health in elderly people

Daily low-dose aspirin does not prolong healthy life in older people, study finds

The use of aspirin in elderly now questioned

FDA approves new treatment for people with hairy cell leukemia

New statement provides detailed overview of how to diagnose, treat resistant hypertension

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Heart attack and stroke prevention efforts need a boost says CDC

Major bleeding associated with subsequent cancer diagnoses

Combined oral anticoagulant and antiplatelet therapy linked to poor prognosis in atrial fibrillation

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

Low dose Aspirin daily – benefits and risks measured in two studies

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

Cardiovascular disease patients with internal bleeding more likely to be diagnosed with cancer

Aspirin appears to cause major bleeds and have no effect on cancers

Customized Micropatterning for Improved Physiological Relevance

Bringing Antimicrobial Susceptibility Testing to the Community

Therapy Dogs Reduce Stress and Improve Emotional Well-Being in Vulnerable Individuals

Latest News